VALNEVA Shares Rise 3.33% Mid-Day, Halting Weekly Decline
The vaccine laboratory's stock significantly rebounds this Wednesday, moving from €3.90 to €4.03 by late morning. This movement marks a welcome reversal of trend after a weakened week, although it occurs in a context of moderate trading volumes. The French biotech remains under medium-term pressure, caught between lowered targets and contrasting technical dynamics.
Mid-Day Recovery
VALNEVA thus gains +3.33% this Wednesday compared to its previous closing, bringing the price to €4.03. This temporary rebound reverses the negative dynamics of the last seven days, during which the stock lost 3.73%. From a broader perspective, the stock remains well-oriented: it has recorded a progression of +24.54% over three months and +44.44% over twelve months, significantly outperforming the CAC 40 which gains 8.82% annually. The Parisian market itself is up +0.08% this Wednesday. However, trading remains sluggish. The share of capital traded represents only 0.15% of the float, indicating limited investor interest at this stage. The stock is well below its three-month target price set by consensus at €6.85, which would imply a rebound potential of around 71.34%. The biotech continues to face significant volatility, with the stock oscillating between a support threshold established at €3.90 and a resistance at €5.09.
Ongoing Adjustments
The Franco-Austrian biopharmaceutical group specializing in vaccines remains in the throes of adjustments following the American decision to suspend the license for its chikungunya vaccine, a decision announced at the beginning of October and which led to a lowering of the 2025 financial forecasts. This downward revision continues to weigh on market sentiment. Concurrently, the results for the first half of 2025 showed an improvement in sales, with €91.0 million generated compared to €68.3 million for the same period in 2024, albeit providing a less robust base than in the past. The company is going through a transition phase where its vaccine solutions are receiving mixed reactions from global regulatory authorities.
Technical Indicators
On the technical front, indicators deliver fragmented signals. The stock is now priced at €4.03, positioned below its 50-day moving average (€4.25) but well above its 200-day moving average (€3.34), indicating a weakened intermediate trend but still supported in the long term. The Relative Strength Index (RSI) reaches 13, a level characteristic of a pronounced oversold situation, generally associated with technical rebounds. The Stochastic shows a buy signal. In contrast, the MACD indicator remains negative, with a MACD line at -0.09 and a signal line at 0.00, while the cumulative volume flow (OBV) records a negative value of -565,262, revealing net capital outflows. The one-month annualized volatility stands at 10.36%, with a sensitivity coefficient (beta) of 0.68, indicating that VALNEVA fluctuates less intensely than the benchmark index. The Bollinger Bands frame the stock between €3.77 and €5.16, outlining a still wide margin of fluctuation.
